Eribulin in breast cancer:Current insights and therapeutic perspectives  

作　　者：Oliver Oey Wynne Wijaya Andrew Redfern 

机构地区：[1]Faculty of Medicine,University of Western Australia,Nedlands 6009,Australia [2]Department of Medical Oncology,Sir Charles Gairdner Hospital,Nedlands 6009,WA,Australia [3]Department of Oncology,University of Oxford,Oxford OX37DQ,United Kingdom [4]Department of Internal Medicine,Universitas Gadjah Mada,Sleman 55281,Indonesia [5]Department of Medical Oncology,Fiona Stanley Hospital,Murdoch 6150,WA,Australia

出　　处：《World Journal of Experimental Medicine》2024年第2期62-74,共13页世界实验医学杂志

摘　　要：Eribulin is a non-taxane synthetic analogue approved in many countries as thirdline treatment for the treatment of patients with metastatic breast cancer.In addition to its mitotic property,eribulin has non-mitotic properties including but not limited to,its ability to induce phenotypic reversal of epithelial to mesenchymal transition,vascular remodelling,reduction in immunosuppressive tumour microenvironment.Since approval,there has been a surge in studies investigating the application of eribulin as an earlier-line treatment and also in combination with other agents such as immunotherapy and targeted therapy across all breast cancer sub-types,including hormone receptor positive,HER2 positive and triple negative breast cancer,many demonstrating promising activity.This review will focus on the application of eribulin in the treatment of metastatic breast cancer across all subtypes including its role as an earlier-line agent,its toxicity profile,and potential future directions.

关 键 词：ERIBULIN Breast cancer Metastatic breast cancer CHEMOTHERAPY Efficacy Safety 

分 类 号：R737.9[医药卫生—肿瘤]